Legumain Antibody (B-11): sc-133124
- Legumain Antibody (B-11) is a mouse monoclonal IgG2a κ provided at 200 µg/ml
- raised against amino acids 21-320 mapping near the N-terminus of Legumain of human origin
- recommended for detection of precursor and mature Legumain of human origin by WB, IP, IF and ELISA
- m-IgG2a BP-HRP and m-IgGκ BP-HRP are the preferred secondary detection reagents for Legumain Antibody (B-11) for WB applications. These reagents are now offered in bundles with Legumain Antibody (B-11) (see ordering information below).
QUICK LINKS
SEE ALSO...
Legumain (B-11) is a mouse monoclonal IgG2a antibody raised against amino acids 1-300 mapping at the N-terminus of Legumain of human origin. Legumain, also known as LGMN, AEP (asparaginyl endopeptidase) or PRSC1, is a 433 amino acid protein that localizes to the lysosome and belongs to the peptidase C13 family. Expressed ubiquitously with particularly high expression in placenta, heart and kidney, Legumain functions as a cysteine protease that specifically catalyzes the hydrolysis of asparaginyl and aspartyl bonds. Additionally, Legumain is thought to be involved in the processing of bacterial proteins for MHC class II antigen presentation in the lysosomal/endosomal system. Legumain exists as both a precursor and a fully mature, active enzyme that is produced in dendritic cells. Overexpression of Legumain may be associated with the formation of solid tumors, suggesting a role for Legumain in carcinogenesis. Multiple isoforms of Legumain exist due to alternative splicing events.
Alexa Fluor® is a trademark of Molecular Probes Inc., OR., USA
LI-COR® and Odyssey® are registered trademarks of LI-COR Biosciences
Legumain Antibody (B-11) References:
- Structure and function of legumain in health and disease. | Dall, E. and Brandstetter, H. 2016. Biochimie. 122: 126-50. PMID: 26403494
- Targeting Legumain As a Novel Therapeutic Strategy in Cancers. | Mai, CW., et al. 2017. Curr Drug Targets. 18: 1259-1268. PMID: 27993111
- Legumain in Pulmonary Arterial Hypertension. | Hilton, LR. and Ormiston, ML. 2019. Arterioscler Thromb Vasc Biol. 39: 536-537. PMID: 30917051
- Recent advances in the development of legumain-selective chemical probes and peptide prodrugs. | Poreba, M. 2019. Biol Chem. 400: 1529-1550. PMID: 31021817
- An Overview of Targeting Legumain for Inhibiting Cancers. | Reddy, BD., et al. 2021. Curr Pharm Des. 27: 3337-3348. PMID: 33238867
- Legumain Is an Endogenous Modulator of Integrin αvβ3 Triggering Vascular Degeneration, Dissection, and Rupture. | Pan, L., et al. 2022. Circulation. 145: 659-674. PMID: 35100526
- Loss of legumain induces premature senescence and mediates aging-related renal fibrosis. | Wang, D., et al. 2022. Aging Cell. 21: e13574. PMID: 35195326
- Cardiac Resident Macrophage-Derived Legumain Improves Cardiac Repair by Promoting Clearance and Degradation of Apoptotic Cardiomyocytes After Myocardial Infarction. | Jia, D., et al. 2022. Circulation. 145: 1542-1556. PMID: 35430895
- CD4+ T-Cell Legumain Deficiency Attenuates Hypertensive Damage via Preservation of TRAF6. | He, Y., et al. 2024. Circ Res. 134: 9-29. PMID: 38047378
- Legumain Regulates Regulatory T Cells in Hypertension. | Alexander, MR. and Harrison, DG. 2024. Circ Res. 134: 30-32. PMID: 38175912
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Legumain Antibody (B-11) | sc-133124 | 200 µg/ml | $322.00 | |||
Legumain Antibody (B-11): m-IgGκ BP-HRP Bundle | sc-534586 | 200 µg Ab; 40 µg BP | $361.00 | |||
Legumain Antibody (B-11): m-IgG2a BP-HRP Bundle | sc-546195 | 200 µg Ab; 10 µg BP | $361.00 |